

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Renal disease				
Renal disease	WAP four-disulfide core domain 2 (WFDC2; HE4)	<p>Studies in patient tissue and in mice suggest antagonizing HE4 could help treat renal fibrosis. In patients with renal fibrosis, HE4 expression was greater in the kidneys and levels of the protein were higher in sera than those in healthy controls. In three mouse models of renal disease, an anti-HE4 antibody decreased fibrosis compared with a control antibody. Next steps could include developing a human mAb targeting HE4.</p> <p><i>SciBX</i> 6(7); doi:10.1038/scibx.2013.172 Published online Feb. 21, 2013</p>	Patent and licensing status unavailable	<p>LeBleu, V.S. <i>et al. Nat. Med.</i>; published online Jan. 27, 2013; doi:10.1038/nm.2989 Contact: Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, Texas e-mail: rkalluri@mdanderson.org</p>